ADEL与赛诺菲签署了一项价值10.4亿美元的全球许可协议,涉及新型阿尔茨海默病研究性疗法ADEL-Y01ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
Sanofi-Aventis is a global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. Co.'s business includes two main activities: pharmaceuticals and human vaccines (Vaccines).